Literature DB >> 17329448

Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies.

Pierre Delobel1, Marie-Thérèse Nugeyre, Michelle Cazabat, Christophe Pasquier, Bruno Marchou, Patrice Massip, Françoise Barre-Sinoussi, Nicole Israël, Jacques Izopet.   

Abstract

Genotypic population-based methods could be faster and less expensive than phenotypic recombinant assays for determining human immunodeficiency virus type 1 (HIV-1) coreceptor usage in patient samples, but their clinical use requires good genotype-phenotype correlation and concordance with clonal analyses. We have assessed these requirements by clonal analysis of the V1 to V3 env PCR products of 26 patients infected with subtype B HIV-1. We used the resulting set of molecular clones, all sequenced and characterized using a single-cycle recombinant virus phenotypic entry assay, to reevaluate genotype-phenotype correlations. Combining the previously described 11/25 and net charge rules for the V3 genotype improved the prediction of HIV-1 coreceptor usage. We also evaluated the concordance of population-based and clonal analyses for predicting the coreceptor usage of HIV-1 quasispecies. Our population-based recombinant phenotypic assay and direct sequencing of V3 were similarly sensitive for detecting the presence of minor species in the virus population, and both correlated well with clonal analysis. The improved genotype-phenotype correlation obtained by combining two simple genotypic rules and the good concordance with clonal analyses suggest that direct sequencing of V3 is a valuable alternative to population-based recombinant phenotypic assays.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329448      PMCID: PMC1865905          DOI: 10.1128/JCM.02090-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages).

Authors:  D R Briggs; D L Tuttle; J W Sleasman; M M Goodenow
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

2.  Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.

Authors:  Noah G Hoffman; Francoise Seillier-Moiseiwitsch; JaeHyung Ahn; Jason M Walker; Ronald Swanstrom
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Authors:  V Trouplin; F Salvatori; F Cappello; V Obry; A Brelot; N Heveker; M Alizon; G Scarlatti; F Clavel; F Mammano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.

Authors:  Pierre Delobel; Marie-Thérèse Nugeyre; Michelle Cazabat; Karine Sandres-Sauné; Christophe Pasquier; Lise Cuzin; Bruno Marchou; Patrice Massip; Rémi Cheynier; Françoise Barré-Sinoussi; Jacques Izopet; Nicole Israël
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

Authors:  S S Hwang; T J Boyle; H K Lyerly; B R Cullen
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

6.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

7.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

Authors:  J J de Jong; J Goudsmit; W Keulen; B Klaver; W Krone; M Tersmette; A de Ronde
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression.

Authors:  Silvina Masciotra; Sherry M Owen; Donna Rudolph; Chunfu Yang; Bin Wang; Nitin Saksena; Thomas Spira; Subhash Dhawan; Renu B Lal
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

10.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  33 in total

1.  Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection.

Authors:  Pierre Frange; Marie-Laure Chaix; Stéphanie Raymond; Julie Galimand; Christiane Deveau; Laurence Meyer; Cécile Goujard; Christine Rouzioux; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

2.  Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism.

Authors:  Stéphanie Raymond; Pierre Delobel; Maud Mavigner; Michelle Cazabat; Corinne Souyris; Stéphanie Encinas; Karine Sandres-Sauné; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2009-05-13       Impact factor: 5.948

3.  HIV gp120 sequence variability associated with HAND in Hispanic Women.

Authors:  Krystal Colón; Fabián Vázquez-Santiago; Vanessa Rivera-Amill; Gisela Delgado; Steven E Massey; Valerie Wojna; Richard J Noel; Loyda M Meléndez
Journal:  J Virol Antivir Res       Date:  2015-10-06

4.  Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory.

Authors:  Christian Paar; Maria Geit; Herbert Stekel; Jörg Berg
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

5.  APOBEC3G/F as one possible driving force for co-receptor switch of the human immunodeficiency virus-1.

Authors:  Eva Heger; Alexander Thielen; Ramona Gilles; Martin Obermeier; Thomas Lengauer; Rolf Kaiser; Susanna Trapp
Journal:  Med Microbiol Immunol       Date:  2011-05-15       Impact factor: 3.402

6.  Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay.

Authors:  Victoria Sánchez; Mar Masiá; Catalina Robledano; Sergio Padilla; José Manuel Ramos; Félix Gutiérrez
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

7.  Frequency of coreceptor tropism in PBMC samples from HIV-1 recently infected blood donors by massively parallel sequencing: the REDS II study.

Authors:  Rodrigo Pessôa; Ester C Sabino; Sabri S Sanabani
Journal:  Virol J       Date:  2015-05-14       Impact factor: 4.099

8.  Genotypic prediction of HIV-1 CRF01-AE tropism.

Authors:  Stéphanie Raymond; Pierre Delobel; Sylvie Rogez; Stéphanie Encinas; Patrick Bruel; Christophe Pasquier; Karine Sandres-Sauné; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

9.  Envelope gene evolution and HIV-1 neuropathogenesis.

Authors:  Fabián J Vázquez-Santiago; Vanessa Rivera-Amill
Journal:  J Neuroinfect Dis       Date:  2015-08-20

10.  HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

Authors:  Maud Mavigner; Pierre Delobel; Michelle Cazabat; Martine Dubois; Fatima-Ezzahra L'faqihi-Olive; Stéphanie Raymond; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.